Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment

Erasca, Inc. has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMS) to evaluate a potential combination treatment for patients with a specific type of pancreatic cancer.

The collaboration will study Erasca’s investigational drug ERAS-0015 alongside navlimetostat (BMS-986504), an investigational PRMT5 inhibitor developed by BMS. The combination will be evaluated in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC), an aggressive form of pancreatic cancer.

Under the agreement, Bristol Myers Squibb will sponsor the clinical trial, while Erasca will supply ERAS-0015. Both companies will retain the development and commercial rights to their respective drug candidates. The agreement is also non-exclusive, allowing both companies to explore other research and development opportunities.

The combination is designed to target two different pathways involved in cancer growth. ERAS-0015 is an oral pan-RAS molecular glue designed to block RAS signalling, which plays an important role in the growth and spread of several cancers. Navlimetostat works by inhibiting PRMT5, an enzyme involved in processes that support cancer cell growth.

The companies believe that targeting both pathways could offer a new treatment approach for patients with MTAP-deleted pancreatic cancer. According to Erasca, nearly all pancreatic cancers with MTAP deletion also carry RAS mutations. This provides a scientific reason to investigate the combination of RAS and PRMT5 inhibitors in this patient group.

ERAS-0015 is currently being evaluated in the AURORAS-1 Phase 1 clinical trial in patients with RAS-mutant solid tumours. Early results from the study have shown favourable safety and tolerability, along with confirmed and unconfirmed partial tumour responses across multiple cancer types.

Some confirmed partial responses were reported at doses as low as 8 mg once daily. However, further clinical studies will be needed to establish the drug’s safety and effectiveness.

Jonathan E. Lim, M.D., Chairman, CEO and Co-founder of Erasca, said the early clinical activity of ERAS-0015 has been encouraging. He added that working with BMS will help the company explore the potential of combining the drug with navlimetostat to improve treatment outcomes for patients with pancreatic cancer.

The collaboration expands Erasca’s efforts to develop combination treatments for RAS-driven cancers. It also brings together two different approaches to targeting cancer-related pathways, with the aim of addressing an important unmet medical need in pancreatic cancer.

The upcoming clinical research will help determine whether the combination of ERAS-0015 and navlimetostat can provide meaningful benefits for patients with MTAP-deleted pancreatic ductal adenocarcinoma.

You might also like